Introduction {#s1}
============

Human coronaviruses (HCoVs) are enveloped viruses with a single-strand RNA genome [@pone.0038638-Greenberg1]. 5 species are known to infect humans, 229E and OC43 first were identified in the 1960s, NL63 and HKU1 identified in 2004 and 2005, respectively [@pone.0038638-Greenberg1]--[@pone.0038638-Woo1], and SARS-CoV was identified during the severe acute respiratory syndrome epidemic in 2003 [@pone.0038638-Drosten1]--[@pone.0038638-Ksiazek1]. HCoVs are associated with respiratory syndromes ranging from mild upper to severe lower respiratory tract infections including pneumonia and bronchiolitis [@pone.0038638-Greenberg1], [@pone.0038638-Fouchier1]--[@pone.0038638-vanderHoek2]. Specifically, HCoVs can elicit a more serious respiratory disease in children, the elderly and people with underlying disease [@pone.0038638-Greenberg1], [@pone.0038638-Fouchier1], [@pone.0038638-NoksoKoivisto1]--[@pone.0038638-Pene1]. HCoVs circulate worldwide, although their frequencies differ from country to country depending on seasonality and detection annum [@pone.0038638-Greenberg1], [@pone.0038638-Esper1]--[@pone.0038638-Suzuki1]. Most studies have focused on children or adults with more serious respiratory disease including lower respiratory tract infections [@pone.0038638-Greenberg1], [@pone.0038638-Dare1]--[@pone.0038638-Vabret1].

Upper respiratory tract infections (URTI) or "the common cold" are a significant health burden, especially among children. The major viral agents of URTI in children include rhinoviruses, HCoVs (--OC43 and --229E), RSV,PIV, adenovirus(ADV) and influenza(Flu). newly identified viruses (hMPV, HCoV-NL63,HCoV-HKU1 and HBoV) are also included. Although HCoVs are recognized as one of the most frequent causes of URTI or common colds in adults [@pone.0038638-Makela1], epidemiological data and clinical profiles are limited on HCoVs infection in adults with URTI continuously for several years with sensitive molecular methods [@pone.0038638-Greenberg1], [@pone.0038638-Gerna1], [@pone.0038638-Gorse1], [@pone.0038638-Gaunt1]--[@pone.0038638-Druce1], especially for HCoV-NL63 and HCoV-HKU1 in China after 2009 H1N1 pandemic. Ren et al reported the prevalence of HCoVs was 1% in adults with ARTI in Beijing from 2005 to 2009 by RT-PCR assays [@pone.0038638-Ren1], which was significantly lower than in previous literatures indicated above 2.1% [@pone.0038638-Greenberg1], [@pone.0038638-Gerna1], [@pone.0038638-Gorse1], [@pone.0038638-Gaunt1]. In the present study, 981 nasopharyngeal swabs were collected continuously from adults with URTI in Beijing between March 2009 and February 2011. HCoVs infections were detected by Real-Time RT-PCR with excellent specifity and sensitivity [@pone.0038638-Esposito1], [@pone.0038638-Gaunt1], [@pone.0038638-Yu1], other 11 respiratory viruses infection among all specimens were also detected by sensitive molecular assays [@pone.0038638-Druce1]--[@pone.0038638-Manning1]. HCoVs infection and their clinical and epidemiological characteristics were analyzed.

Materials and Methods {#s2}
=====================

Ethics Issues {#s2a}
-------------

All aspects of the study were performed in accordance with the national ethics regulations and approved by the Institutional Review Boards of the Centre for Disease Control and Prevention of China, as well as the Ethics Committee of Peking Union Medical College Hospital. Participants were received \"Written Informed Consent\" on the study's purpose and of their right to keep information confidential. Written consent was obtained from all participants or their guardians.

Patients and Specimens {#s2b}
----------------------

Nasopharyngeal swabs were collected from adults presenting with URTI to the Peking Union Medical College Hospital, Beijing, China, between March 2009 and February 2011. Patients provided informed consent for specimen collection and testing. All patients over 14 years of age were selected according to a set of criteria that included respiratory symptoms, a body temperature above 37.5°C, and a normal or low leukocyte count(≤10^10^/L), but not LRTI identified by pulmonary abnormalities on radiography and clinical descriptions(without bronchitis, bronchiolitis and pneumonia). Demographic data and clinical findings at the time of diagnosis were recorded on a standard form. All swabs were collected into viral transport medium and transported for immediate testing to the National Institute for Viral Disease Control and Prevention (NIVDC), China Center for Disease Control and Prevention.

Nucleic Acid Extraction and cDNA Synthesis {#s2c}
------------------------------------------

Viral RNA was extracted from 200 µl of sample using QIAamp MinElute Virus Spin kits (Qiagen, Germany). cDNA was synthesized with AMV reverse transcriptase and random hexamer primers (Promega, USA) as described previously [@pone.0038638-Esposito1], [@pone.0038638-Gaunt1], [@pone.0038638-Druce1].

Real-time RT-PCR for HCoV Detection {#s2d}
-----------------------------------

Real-time RT-PCR amplification was performed using TaqMan® One-Step RT-PCR Master Mix Reagents Kit (Applied Biosystems, USA) [@pone.0038638-Esposito1], [@pone.0038638-Gaunt1], [@pone.0038638-Yu1]. A real-time reverse transcription (RT)-PCR technique was used to screen for each of the 4 non-SARS HCoVs ([Table 1](#pone-0038638-t001){ref-type="table"}). PCR was performed under the following conditions: 48°C for 30 min, 95°C for 15 min, followed by 40 cycles at 95°C for 15s, 68°C for 1min.The lower limit of detection of each HCoV real-time RT-PCR assay was 50--100 copies/25uL.The assay sensitivity, specificity and coefficients of variability(CVs) were evaluated and validated as previously described [@pone.0038638-Esposito1], [@pone.0038638-Yu1].

10.1371/journal.pone.0038638.t001

###### Primers and Probes (5′--3′), and Their Gene Product Targets, Used for the Respiratory Viruses Identified in the Study.

![](pone.0038638.t001){#pone-0038638-t001-1}

  Assays andViruses detected              Primer[\*](#nt101){ref-type="table-fn"} and probe   Target genes   Ref
  ---------------------------- --------- --------------------------------------------------- -------------- -----
  **Real-time rtPCR**                                                                                       
  HCoV-OC43                     OC43-F                   GCTCAGGAAGGTCTGCTCC                       N         19
                                OC43-R                  TCCTGCACTAGAGGCTCTGC                                
                                OC43-P          FAM --TTCCAGATCTACTTCGCGCACATCC-TAMRA                       
  HCoV-229E                     229E-F                  CGCAAGAATTCAGAACCAGAG                      N         19
                                229E-R                  GGCAGTCAGGTTCTTCAACAA                               
                                229E-P        FAM --CCACACTTCAATCAAAAGCTCCCAAATG-TAMRA                      
  HCoV-NL63                     NL63-F               AGGACCTTAAATTCAGACAACGTTCT                    N         19
                                NL63-R                GATTACGTTTGCGATTACCAAGACT                             
                                NL63-P     FAM- TAACAGTTTTAGCACCTTCCTTAGCAACCCAAACA-TAMRA                   
  HCoV-HKU1                     HKU1-F                 AGTTCCCATTGCTTTCGGAGTA                      N         19
                                HKU1-R                CCGGCTGTGTCTATACCAATATCC                              
                                HKU1-P                FAM -CCCCTTCTGAAGCAA- MGB                             
  **Multiple-nested PCR**                                                                                   
  **Mix1** FluA                  FA-1F                 CAGAGACTTGARRATGTYTTTGC                   Matrix      26
                                 FA-1R                GGCAAGYGCACCRGYWGARTARCT                              
                                 FA-2F                 GACCRATCCTGTCACCTCTGACT                              
                                 FA-2R                 AYYTCYTT GC CCATGGAATGT                              
  FluB                           FB-1F                  GTGACTGGTGTGATACCACT                       HA       
                                 FB-1R                  TGTTTTCACCCATATTGGGC                                
                                 FB-2F                  CATTTTGCAAATCTCAAAGG                                
                                 FB-2R                  TGGAGGCAATCTGCTTCACC                                
  ADV                            AD-1F                GCCGCAGTGGTCTTACATGCACATC                  Hexon      
                                 AD-1R                 CAGCACGCCGCGGATGTCAAAGT                              
                                 AD-2F                GCCACCGAGACGTACTTCAGCCTG                              
                                 AD-2R              TTGTACGAGTACGCGGTATCCTCGCGGTC                           
                                AD-2F9                  CMGASACSTACTTCAGYMTG                                
                                AD-2R9                  GTASGYRKTRTCYTCSCGGTC                               
  **Mix2** hRSV                  RS-1F               TGGGAGARGTRGCTCCAGAATACAGGC                   N         26
                                 RS-1R               ARCATYACTTGCCCTGMACCATAGGC                             
                                 RS-2F                   ACYAAATTAGCAGCAGGG                                 
                                 RS-2R                   CTCTKGTWGAWGATTGTGC                                
  Picornavirus                  PIC-1F                    GCACTTCTGTTTCCCC                       5?-UTR     
                                PIC-1R                    CGGACACCCAAAGTAG                                  
                                PIC-2F                    GCACTTCTGTTTCCCC                                  
  **Mix3** PIV (-1,-2,-3)       P123-1F                 GTWCAAGGAGAYAATCARGC                       L         26
                                P123-1R                  GRTCYGGAGTTTCWARWCC                                
                                 P1-2F                  GCATCAGACCCTTATTCATG                                
                                 P1-2R                  GTTGTATCAAGCATCCCGGC                                
                                 P2-2F                  CAGCCGATCCATACTCATTG                                
                                 P2-2R                  CTTGTGGTGTCAAAAAATCC                                
                                 P3-2F                  GCTGTTACTACAAGAGTACC                                
                                 P3-2R                  GTTGCCAGATTTGAGGATGC                                
  **rtPCR**                                                                                                 
  hMPV                          hMPV-F                AACCGTGTACTAAGTGATGCACTC                     N         27
                                hMPV-R                 CATTGTTTGACCGGCCCCATAA                               
  **Nested PCR**                                                                                            
  HBoV                          HBoV-1F              CCAGCAAGTCCTCCAAACTCACCTGC                   NP-1       28
                                HBoV-1R              GGAGCTTCAGGATTGGAAGCTCTGTG                             
                                HBoV-2F                 GACCTCTGTAAGTACTATTAC                               
                                HBoV-2R                 CTCTGTGTTGACTGAATACAG                               

K  =  G+T, M  =  A+C, R  =  A+G, S  =  G+C, W  =  A+T, Y  =  C+T.

1st round primers:--1F,--1R; 2 nd round primers: --2F or --2F9, --2R or --2R9.

Gel-based RT-PCR for Detection of non-HCoV Respiratory Viruses {#s2e}
--------------------------------------------------------------

Specimens were also screened for influenza virus types A and B, parainfluenza virus types 1 to 3, respiratory syncytial virus (RSV), picornaviruses (including enteroviruses and rhinoviruses) and adenoviruses using three multiple-nested PCR assays [@pone.0038638-Druce1]--[@pone.0038638-Yu1] ([Table 1](#pone-0038638-t001){ref-type="table"}), for human metapneumovirus (hMPV) and human bocavirus (HBoV) using PCR and nested-PCR assays [@pone.0038638-Yu1]--[@pone.0038638-Manning1] ([Table 1](#pone-0038638-t001){ref-type="table"}). Multiple-nested PCR and nested PCR programs were run as follows: 1^st^ round: 94°C for 2 min; 94°C for 30 s, 55/50°C 30 s, 72°C for 1 min, 35 cycles; 72°C 5 min. 2^nd^ round: 94°C for 2 min; 94°C for 30s, 55/50°C 30s, 72°C for 1 min, 25 cycles; 72°C 5 min. RT-PCR program was run as follows: 50°C 30 min; 95 °C 15 min; 95°C 30s, 60°C 30s, 72°C 1 min, 40 cycles; 72°C 5 min. The lower limits of detection for nested PCR and RT-PCR assays were 10--100 single virus molecules/25 ul. All PCR products were confirmed by sequencing.

Statistical Analysis {#s2f}
--------------------

Statistical analysis was performed using the predictive analysis software (PASW) statistics 18 package with X^2^-test and Fisher's exact test.

Results {#s3}
=======

Detection of HCoVs and Other 11 Respiratory Viruses Infection {#s3a}
-------------------------------------------------------------

A total of 981 nasopharyngeal swabs were collected. The male: female ratio was 438∶543 (1∶1.24) and the median age was 29 years (age range 14 years to 91 years). HCoVs were detected by real-time RT-PCR in 157 (16.0%) of the 981 specimens: 229E in 96 (9.8%), OC43 in 42 (4.3%), HKU1 in 16 (1.6%) and NL63 in 11(1.1%). The detection rates of HCoVs are summarized in [Table 2](#pone-0038638-t002){ref-type="table"}. Differences in the detection rates of OC43 and NL63 during 2009/10 and 2010/11 were statistically significant (P\<0.001 and P = 0.003, respectively).

10.1371/journal.pone.0038638.t002

###### Prevalence of Different Respiratory Virus Infections from March 2009 to February 2011.
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  Respiratory Virus               No. of detections (%)                Total              
  ------------------- ---------------------------------------------- ---------- --------- ---------
  HCoV-OC43             38(7.1)[\*\*](#nt103){ref-type="table-fn"}     4(0.9)    42(4.3)  
  HCoV-229E                              58(10.8)                     38(8.6)    96(9.8)  
  HCoV-NL63                             11(2.0) \*                      0(0)     11(1.1)  
  HCoV-HKU1                              12(2.2)                       4(0.9)    16(1.6)  
  Flu A                84(15.6) [\*\*](#nt103){ref-type="table-fn"}    3(0.7)    87(8.9)  
  Flu B                                  17(3.2)                       1(0.2)    18(1.8)  
  PIV-1                                   4(0.7)                       1(0.2)    5(0.5)   
  PIV-2                                   1(0.2)                        0(0)     1(0.1)   
  PIV-3                                    0(0)                         0(0)      0(0)    
  ADV                                    19(3.5)                       1(0.2)    20(2.0)  
  hRSV                                    1(0.2)                        0(0)     1(0.1)   
  Piconavirus                          Rhinoviruses                   57(10.6)   14(3.2)   71(7.2)
                                       Enterovirus                     7(1.3)     0(0)     7(0.7)
  hMPV                                   13(2.4)                      13(2.9)    26(2.7)  
  HBoV                                     0(0)                        2(0.5)    2(0.2)   

P\<0.001; \*P = 0.003.

Other 11 respiratory viruses infection among all specimens were also detected by sensitive molecular assays ([Table 1](#pone-0038638-t001){ref-type="table"}). During the same period, Flu A virus was detected in 87(8.9%) patients, Flu B virus was detected in 18(1.8%) patients, PIV-1 was detected in 5(0.5%) patients, PIV-2 was detected in 1(0.1%) patient, ADV was detected in 20(2.0%) patients, RSV was 1(0.1%) patient, rhinoviruses was detected in 71(7.2%) patients, enterovirus was detected in 7(0.7%) patients, hMPV was detected in 26(2.7%), and HBoV was detected in 2(0.2%) patients([Table 2](#pone-0038638-t002){ref-type="table"}).

Epidemiology of HcoVs {#s3b}
---------------------

The seasonal distribution of HCoVs is shown in [Fig.1](#pone-0038638-g001){ref-type="fig"}. HCoV-229E was the most common species, appearing in most months and without an obvious seasonal distribution. Peaks in 229E detections occurred in May 2009, December 2009 and August 2010, corresponding with spring, winter and summer, respectively, in Beijing. HCoV-OC43 detections peaked in April 2009. This virus continued to circulate for the next 10 months but only sporadic infections were detected in the second half of the study. In 2009, when most coronavirus infections occurred, 229E and OC43 were detected in every evaluable month, with the exception of 229E in September. A peak of NL63 activity occurred in March and April 2009 with little or no subsequent activity. HCoV-HKU1 activity was sporadic throughout, with no obvious seasonal distribution.

![Temporal distribution of the 4 HCoV species between March 2009 and February 2011 inclusive.](pone.0038638.g001){#pone-0038638-g001}

HCoVs were detected across all age groups, although NL63 cases were absent in the 30--39 years age group ([Fig.2](#pone-0038638-g002){ref-type="fig"}). A significantly higher detection frequency of HKU1 occurred in patients aged over 60 years (P = 0.03), but there were no significant differences in age group distribution for 229E, OC43 and NL63.

![Frequencies of the four non SARS HCoVs infections detection by different age groups.](pone.0038638.g002){#pone-0038638-g002}

Clinical Characteristics of Patients with HCoVs Infection {#s3c}
---------------------------------------------------------

Approximately equal numbers of males and females were infected with OC43, HKU1 and NL63; 229E infected significantly more female than males (62.5% versus 37.5%, P = 0.009). The clinical characteristics are summarized in [Table 3](#pone-0038638-t003){ref-type="table"}. All HCoV positive patients presented with URTI. Fever, sore throat and headache were the most common symptoms at presentation. Gastrointestinal tract associated symptoms were rare. Overall there were no statistically significant differences in the clinical symptoms between species-specific HCoVs except for rhinorrhea, which was observed less in 229E-infected patients than in the other cases (P = 0.025).

10.1371/journal.pone.0038638.t003

###### Clinical characteristics of patients with HCoV infections in the study.
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  Characteristics                   OC43 (N = 42)   229E (N = 96)   NL63 (N = 11)   HKU1(N = 16)   P-value
  -------------------------------- --------------- --------------- --------------- -------------- ----------
  **Demographics:**                                                                               
  Gender ratio (M/F)                     1.1            0.58            0.83            0.78      
  Age in years mean/median            33.5/28.5        32.3/28        41.45/41       38.1/31.5    
  **Respiratory symptoms:**                                                                       
  Fever(\>38°C)                      37 (88.1%)      79 (82.3%)      10 (90.9%)      12 (85.7%)       ns
  Chills                              6 (14.3%)       24 (25%)        2 (18.2%)       4 (25%)         ns
  Sore throat                        27 (64.3%)      63 (65.6%)       8 (72.7%)      10 (62.5%)       ns
  Nasal obstruction                   9 (21.4%)      18 (18.8%)       3 (27.3%)      2 (12.5%)        ns
  Rhinorrhea                         17 (40.5%)       23 (24%)        5 (45.5%)      9 (56.2%)      = 0.025
  Cough                              14 (33.3%)      30 (31.2%)       7 (63.6%)      9 (56.3%)        ns
  Sputum production                    8 (19%)       16 (16.7%)       5 (45.5%)       4 (25%)         ns
  **Gastrointestinal symptoms:**                                                                  
  Vomiting                            4 (9.5%)        5 (5.2%)        1 (9.1%)           0            ns
  Diarrhea                            1 (2.4%)        6 (6.2%)        1 (9.1%)           0            ns
  **Other symptoms:**                                                                             
  Headache                           30 (71.4%)      68 (70.8%)       5 (45.5%)      11 (68.8%)       ns
  Muscle pain                         1 (2.4%)        4 (4.2%)            0           1 (6.3%)        ns

Co-detections of other Respiratory Virus in HCoV-positive Cases {#s3d}
---------------------------------------------------------------

High rates of co-infection with non-HCoV respiratory viruses were observed ([Table 4](#pone-0038638-t004){ref-type="table"}). Of the 157 HCoV positive patients, 48 (30.57%) were co-infected, 38 of them with one other virus and 10 with 2 other viruses. Most HCoV-associated co-infections involved human rhinoviruses (all picornaviruses positive samples were confirmed to be rhinoviruses by DNA sequencing) and Flu A virus (more than 30%). Compared to single HCoV infections, there was no evidence to indicate that patients with co-infections had more serious illnesses (results not shown).

10.1371/journal.pone.0038638.t004

###### Co-Detections of HCoVs and other Respiratory Virus in the study population.
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  Co-Detection withHCoVs(n = 157)                           Number of cases (n = 48)
  -------------------------------------------------------- --------------------------
  **HCoVs+ Flu A**                                                     18
  229E+ Flu A                                                          10
  NL63+ Flu A                                                          1
  HKU1+ Flu A                                                          2
  OC43+229E+ Flu A                                                     2
  OC43+HKU1+ Flu A                                                     2
  NL63+HKU1 + Flu A                                                    1
  **HCoVs +Flu B**                                                     1
  229E+Flu B                                                           1
  **HCoV+ ADV**                                                        6
  OC43+ADV                                                             3
  229E+ADV                                                             2
  NL63+ADV+rhinoviruses[\*](#nt104){ref-type="table-fn"}               1
  **HCoVs+ hRSV**                                                      1
  OC43+HKU1+hRSV                                                       1
  **HCoVs+ rhinoviruses**                                              18
  OC43+rhinoviruses                                                    5
  229E+rhinoviruses                                                    9
  HKU1+rhinoviruses                                                    1
  OC43+NL63+rhinoviruses                                               1
  NL63+HKU1+rhinoviruses                                               1
  NL63+ADV+rhinoviruses[\*](#nt104){ref-type="table-fn"}               1
  **HCoVs+hMPV**                                                       1
  229E+hMPV                                                            1
  **HCoVs+HCoVs**                                                      4
  OC43+229E                                                            3
  OC43+229E+NL63                                                       1

Be only counted once in the total.

Discussion {#s4}
==========

HCoVs circulate worldwide and the prevalence of the different species varies by year and geographical location [@pone.0038638-Greenberg1]. Recent reports show that HCoVs have been detected in Hong Kong [@pone.0038638-Lau1], Italy [@pone.0038638-Gerna1], France [@pone.0038638-Vabret1], [@pone.0038638-Vabret2], USA [@pone.0038638-Dominguez1], [@pone.0038638-Talbot1], [@pone.0038638-Kuypers1], UK [@pone.0038638-Gaunt1], Netherlands [@pone.0038638-Esposito1], Finland [@pone.0038638-Risku1], and China [@pone.0038638-Ren1]--[@pone.0038638-Druce1] in respiratory and/or stool samples obtained from young children [@pone.0038638-Dominguez1], [@pone.0038638-Talbot1]--[@pone.0038638-Vabret1], [@pone.0038638-Kuypers1] and adults [@pone.0038638-Gorse1], [@pone.0038638-Gaunt1]--[@pone.0038638-Ren1], [@pone.0038638-Garbino1]. In our retrospective study, a 16.0% detection rate for HCoVs infection was found in adults with URTI; 229E was the most common infection (9.8% of all cases), followed by OC43 (4.3%), HKU1 (1.6%) and NL63 (1.1%). The detection rates for 229E and OC43 are consistent with other studies performed worldwide (0.1--26% &0.5--10.1%) [@pone.0038638-Greenberg1], [@pone.0038638-Pene1], [@pone.0038638-Vabret1], [@pone.0038638-Yu1], [@pone.0038638-Lau1]--[@pone.0038638-Mahony1], but higher than in a recent study undertaken in Beijing [@pone.0038638-Ren1], perhaps due in our study to the exclusion of patients with lower respiratory tract infections via clinical descriptions and radiography, the use of a screening criteria leukocyte count of ≤10^10^/L which is likely to have excluded most patients with bacterial infection, and the use of real-time PCR with excellent sensitivity [@pone.0038638-Dare1], [@pone.0038638-Esposito1], [@pone.0038638-Gaunt1]. The studies were also undertaken in different years, suggesting that the presence or absence of circulating HCoV species during these times may have influenced these differed outcomes [@pone.0038638-Greenberg1], [@pone.0038638-Dare1], [@pone.0038638-Ren1]. In addition, Flu A detection rate was 15.6% among URTI adult patients between 2009/2--2010/3 with the occurrence of pandemic H1N1 virus 2009, which was signicantly higher than that (0.7%) of patients between 2010/2--2011/3 ([Table 2](#pone-0038638-t002){ref-type="table"}). Whether the circulating patterns of HCoVs might be affected by FluA pandemic, warrants further studies.

HCoVs exhibit variable circulation approximately every 2--3 years [@pone.0038638-Greenberg1], [@pone.0038638-Dare1], [@pone.0038638-Ren1], [@pone.0038638-Shao1]--[@pone.0038638-Bellei1], and this was confirmed by our observation that detection rates for both OC43 and NL63 were statistically significant between 2009/10 and 2010/11. Nevertheless, 229E strains circulated throughout the 2 years of study, often in high numbers and without discernible seasonality, in contrast to that reported in the UK [@pone.0038638-Gaunt1].

A previous study in Beijing reported higher detection rates for HCoVs in individuals over 65 years of age [@pone.0038638-Ren1]. In contrast, in this study HCoVs were detected essentially in all adult age groups. Of note, however, HKU1 infection predominated in patients aged over 60 years, suggesting that adults in this category may be at higher risk for infection with this species.

URTI occurs commonly in both children and adults and is a major cause of mild morbidity which have a high cost to society. URTI among adults are responsible for missed work and unnecessary medical care (antibiotic prescriptions), also occasionally associated serious sequelae. The clinical diagnosis of all HCoVs positive patients we studied was URTI. The main clinical signs at presentation were fever, cough, sore throat and headache, in accord with several previous studies [@pone.0038638-Greenberg1], [@pone.0038638-Makela1], [@pone.0038638-Vabret1]. Some cases also showed gastrointestinal symptoms except in HCoV-HKU1 infection patients [@pone.0038638-Greenberg1], [@pone.0038638-Risku1]. Rhinorrhea was observed in significantly fewer patients infected with 229E. Many previous reports have indicated that HCoVs have high rates of co-infection with other respiratory viruses [@pone.0038638-Greenberg1], [@pone.0038638-Esposito1], [@pone.0038638-Gaunt1], [@pone.0038638-Yu1], including rhinoviruses, influenza, HMPV, ADV and RSV. In this study, co-infections were associated with each of the non-SARS HCoVs at rates similar to previous studies [@pone.0038638-Greenberg1], [@pone.0038638-Dominguez1], [@pone.0038638-Gaunt1], [@pone.0038638-Yu1]. Human rhinoviruses and influenza A viruses were the most common respiratory viruses detected in HCoVs-positive patients, possibly reflect the level of their circulation at the time, and which were consistent with rhinoviruses being the most common respiratory viruses for common cold [@pone.0038638-Greenberg1], [@pone.0038638-Heikkinen1]. In contrast with virus infection among children with URTI [@pone.0038638-Greenberg1], [@pone.0038638-Makela1], [@pone.0038638-Gaunt1], [@pone.0038638-Heikkinen1], RSV, PIV and HBoV were detected in very low rate(less than 1%) among adults with URTI in this study. It was consistent with the previous reports [@pone.0038638-Yu1], [@pone.0038638-Mahony1]. Comparison of clinical symptoms experienced by patients with and without co-infections indicated that co-infection with HCoVs did not affect illness severity.

In summary, we found that the four non-SARS HCoVs are regularly associated with URTI in adult patients in China, although distinct seasonal patterns of circulation are not obvious. Our observation that elderly adults may be are at high risk of HKU1 infection requires further study. Our results suggest that testing algorithms that include sensitive HCoVs detection contribute to the likelihood of obtaining a laboratory diagnosis when respiratory virus infection is suspected [@pone.0038638-Yu1], [@pone.0038638-Mahony1]--[@pone.0038638-Pyrc1]. To the best of our knowledge, this is the first comprehensive analysis of the potential impact of four non-SARS HCoVs (HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1) as causes of URTIs in adults admitted to hospital in China by real time RT-PCR assays. To identify the role of HCoVs infection in URTI of adults, more specimens include control subjects with clear clinical and epidemiological profiles warrant be investigated.
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